In the completed Phase 2 trial in r/r AML, SLS009 in combination with aza/ven met all endpoints, exceeding the pre-specified ORR threshold of 20%, demonstrating strong efficacy and favorable safety ...
Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilize ...
Donald Trump's war against Iran is part of a terrifying new era of American imperialism, one in which the military budget never stops growing.
Zacks Investment Research on MSN
EDIT stock up on narrower-than-expected Q4 loss, revenues rise Y/Y
Editas Medicine EDIT reported a loss of 6 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 55 cents ...
Major Chinese technology companies, including Tencent Holdings and TikTok's parent company ByteDance, are competing fiercely ...
Microsoft's Phi-4-reasoning-vision-15B uses careful data curation and selective reasoning to compete with models trained on ...
AI tools, love them or hate them, have been a big deal in coding and app development, and Google is now actively testing out what the best tools are for Android app development h ...
Zevra Therapeutics, Inc. is rated a Buy, delivered robust FY25 results, with 350% revenue growth to $106.5M. Learn more about ZVRA stock here.
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results